Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00804336 · ClinicalTrials.gov registry record · Phase 1
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00804336 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 22 participants.
The verdict
NCT00804336, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely. SOM230 is an investigational drug that is similar to Sandostatin LAR. Sandostatin is an approved drug for the use of treating symptoms of neuroendocrine tumors. SOM230 has shown to be effective in patients who have become resistant to Sandostatin and may also stop cancer cells from growing. RAD001 is an investigational drug that also may stop cancer cells from growing.
Interventions
- DRUG RAD001
- DRUG SOM230
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00804336
The ClinicalTrials.gov registry entry for NCT00804336 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RAD001 is the first listed.
NCT00804336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00804336 about?
NCT00804336 is a clinical study titled "Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors". The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely. SOM230 is an investigational drug that is similar to Sandostatin LAR. Sandostatin is an approved drug f...
What is the current status of trial NCT00804336?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00804336?
The interventions under investigation include: RAD001 (DRUG), SOM230 (DRUG).
Who is sponsoring clinical trial NCT00804336?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.